Cite
Cabozantinib in neuroendocrine tumors: tackling drug activity and resistance mechanisms.
MLA
Cella, Chiara Alessandra, et al. “Cabozantinib in Neuroendocrine Tumors: Tackling Drug Activity and Resistance Mechanisms.” Endocrine-Related Cancer, vol. 30, no. 12, Dec. 2023, pp. 87–98. EBSCOhost, https://doi.org/10.1530/ERC-23-0232.
APA
Cella, C. A., Cazzoli, R., Fazio, N., De Petro, G., Gaudenzi, G., Carra, S., Romanenghi, M., Spada, F., Grossi, I., Pallavicini, I., Minucci, S., & Vitale, G. (2023). Cabozantinib in neuroendocrine tumors: tackling drug activity and resistance mechanisms. Endocrine-Related Cancer, 30(12), 87–98. https://doi.org/10.1530/ERC-23-0232
Chicago
Cella, Chiara Alessandra, Riccardo Cazzoli, Nicola Fazio, Giuseppina De Petro, Germano Gaudenzi, Silvia Carra, Mauro Romanenghi, et al. 2023. “Cabozantinib in Neuroendocrine Tumors: Tackling Drug Activity and Resistance Mechanisms.” Endocrine-Related Cancer 30 (12): 87–98. doi:10.1530/ERC-23-0232.